Fairtility has launched a new educational platform to highlight the importance of AI in fertility care.
The AI Academy was officially announced at this month’s European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Milan.
Dr Gerard Letterie, a reproductive endocrinology expert and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.
He has introduced the first AI Academy session, followed by a panel discussion with four of the most recognised authorities in the field of IVF.
“At ESHRE, we confirmed our understanding of the state of AI in IVF,” says Dr Letterie. “The field is evolving and maturing rapidly and the uptake of these tools hinges on education and understanding.
“The industry knows that AI presents an important opportunity in fertility care, but does not fully understand what capabilities and limitations exist, nor what to expect out of AI in this field. Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care.”
The infertility specialist adds: “IVF professionals will develop a deeper understanding of this technology and how it can serve them in their work, and ultimately, improve IVF outcomes for prospective parents. I am honoured to head the AI Academy with the support of Fairtility.”
Eran Eshed, CEO and co-founder of Fairtility, says that investing in education for IVF professionals will help them better understand the potential for AI to transform the IVF industry. “We believe that knowledge is the best tool to resolve concerns of the unknown and help usher in the capabilities of AI to advance the efficacy of IVF treatment.
“We are building a community of experts and creating a space for dialogue, the sharing of ideas, innovation and productive argumentation – all in an effort to advance our industry to its fullest potential.”
The AI Academy will host a roster of speakers covering a range of topics from the basics of AI, AI and the IVF lab, AI in clinical and management, as well as ethics and best practices in AI’s application.
The first AI Academy session called, “AI, the new frontier: Everything you need to know about this tech” will take place on September 2 and will be led by Dr Nadav Rapoport of Ben Gurion University’s department of software and information systems engineering.
“We see expanding interest as AI technology for IVF continues to advance, yet there are no definable parameters or baselines for AI’s adoption in this industry,” Eshed adds.
“Our AI Academy is poised to centre the pendulum on AI by establishing a coherent, organised field that provides accessible education and conversation, bringing early and late adopters together to shorten the innovation adoption cycle for AI in fertility care.”
The Israeli software company aims to maximise IVF outcomes by using AI and computer vision algorithms to analyse morphological and morphokinetic features and provide early, data-driven embryo quality.
For more info, visit fairtility.com/AIAcademy.
How we can address the gender imbalance in fertility testing
Everyone has heard of the female biological clock, but not many people know that male fertility declines throughout adulthood too
Although one in six couples globally have difficulty conceiving, infertility remains a woman’s social burden. We need to address male infertility, says Lily Elsner.
Infertility affects 186 million people worldwide and, despite everything society has led us to believe, one-third of infertility cases are caused by male reproductive issues.
Male infertility can be caused by low sperm production, abnormal sperm function or blockages that prevent the delivery of sperm. Some men may also experience fertility issues due to chronic health problems, illnesses and lifestyle choices.
How come no one talks about it? To date, fertility has been firmly cast as a “woman’s issue”, irrespective of men being half of the fertility equation.
Everyone has heard of the female biological clock, but not many people realise that male fertility declines throughout adulthood too. Research shows that men will generally see a 52 per cent decrease in fertility rate between their early 30s and their mid-to-late 30s.
“Male infertility, although often treatable, is a very taboo subject,” says Lily Elsner, co-founder and CEO of Jack Fertility.
“Because men don’t have the same relationship with their physicians as women do, they often don’t know they could do something about it.”
Culturally, it can also be hard for men to talk about having trouble conceiving as this can be seen as a lack of masculinity.
Research shows that the majority of men (73 per cent) are unlikely to talk about their infertility with others. In fact, 39 per cent are not likely to talk about their infertility at all.
Elsner, however, thinks we can change that. As the woman behind Jack Fertility’s at-home sperm test kit, she thinks talking openly about male infertility could go a long way towards addressing the gender imbalance in fertility testing.
“The whole point of femtech is to ensure women’s health is prioritised. By opening up the conversation around reproductive health and making it easy to assess male fertility, we can take some of the pressure off of women.
“Some men may not want to talk about their infertility still, but it’s an essential component of creating an equal world for all genders. I am tired of watching women shoulder the majority of infertility’s physical and emotional burden, and seeing men and non traditional families completely neglected in the medical and societal discourse surrounding fertility.”
A test like Jack, Elsner says, could give people that empowerment of having access to their health data and provide them with the tools to be able to make the right decision for them.
“A lot of men think of fertility as static, when really the male body is constantly creating sperm. With Jack, what we are trying to say is, ‘Actually, your fertility massively depends on your current health and chronic illnesses’.
“Our aim is to make it easy and convenient for all men to get reliable results about the status of their fertility, even if they are not considering starting a family. That’s part of why we named the company Jack – it’s cheeky and relatable.”
There are many fertility test on the market, but Elsner doesn’t see that as a bad thing.
“The rise of companies providing at-home sperm testing suggests a growing interest in male reproductive health, but it also signals a shift in attitudes, with fertility being recognised as an issue that affects both men and women equally,” she says.
“There are so many amazing companies out there working on fertility tests, but I think most of them are targeted a little bit further down the funnel. For us, it’s about getting men to take that first important step of getting tested. We just want them to have a chat with Jack.”
Jack Fertility is expected to launch later this year. To find out more, visit jackfertility.co.uk.
Partnership to pilot ‘cutting-edge’ embryo selection tool
The partnership is hoped to streamline laboratory operations with the potential future benefit of optimising the embryo selection process
The US fertility technology company Alife Health has teamed up with a network of laboratories to pilot an AI technology for embryo image capture and cataloguing.
The company’s partnership with Ovation Fertility aims to focus on streamlining laboratory operations with the potential future benefit of optimising the embryo selection process.
The technology could enable future “AI-powered” embryo selection.
Alife’s Embryo Assist software promises to help embryologists to create digital records of every embryo, with the added benefit of using the start-up’s clinical decision support algorithm to determine the best embryo for transfer.
Paxton Maeder-York, founder and CEO of Alife, said: “We are thrilled to join forces with Ovation, a leading laboratory network in the country, to showcase the transformative impact of Alife’s technology.
“Through this partnership, we aim to demonstrate how Alife’s advanced technology, powered by AI, can not only optimise clinic workflow, but also set a new standard in the precision and consistency of embryo selection.
“We look forward to contributing to Ovation’s commitment to excellence in fertility care.”
Matthew VerMilyea, vice president of scientific advancement at Ovation, added: “At Ovation, we strive to discover and leverage the most state-of-the-art technologies available to us in order to better improve patient outcomes.
“The Alife Embryo Assist software provides our laboratories with a structured digital approach to a rather manual and cumbersome process.
“I believe that by implementing Alife’s technology, we will see an improvement in lab efficiency and performance, which ultimately will help our network provide the best possible outcomes for every individual hoping to grow their family.”
The Embryo Assist software claims to allow embryologists to capture images of each embryo and streamline the embryo reporting process by eliminating the need to manually transcribe information between systems.
Alife expects the tool to “elevate” laboratory quality-control measures by providing an activity and audit trail for every embryo, viewable in real time.
Kitazato and IVF2.0 forge groundbreaking collaboration to revolutionise IVF with AI solutions
The collaboration aims to advance real-time sperm selection for intracytoplasmic sperm injection (ICSI) and embryo ranking
Kitazato, a trailblazing Japanese corporation specialising in assisted reproduction products, and IVF2.0, a leader in AI software for assisted reproductive technology (ART), have joined forces in a strategic collaboration.
The partnership aims to advance real-time sperm selection for intracytoplasmic sperm injection (ICSI), and embryo ranking based on ploidy prediction, ushering in a new era for the IVF market.
Under this agreement, Kitazato will leverage its multi-national distribution network to introduce standardised reproducible data-driven decision-making to IVF laboratories in many regions of the world through IVF2.0’s software.
IVF2.0’s suite of AI tools, including sperm selection (SiD) and embryo selection (ERiCA), assists embryologists in making critical choices to optimize fertility outcomes.
Mr Futoshi Inoue, president and CEO of Kitazato, expresses enthusiasm, stating: “Partnering with IVF2.0 demonstrates our commitment to innovation. We embrace technologies that aim to boost success rates, standardize procedures, and democratize fertility treatment for all.”
Professor Andrew Drakeley, co-founder and board chair of IVF2.0, emphasises the significance of the collaboration.
He said: “Our bond with Kitazato, a prestigious company with world-class products, underscores the growing need for implementing AI tools in IVF clinics globally. This marks a substantial step in the right direction.”
Kitazato, Kitazato – Quality Results for Life (kitazato-ivf.com), renowned for delivering quality products in assisted reproduction, aligns with IVF2.0’s mission to enhance IVF outcomes through AI.
IVF2.0’s innovative software platform employs AI and computer vision technology to elevate key steps in the IVF process.
Learn more at IVF 2.0 (ivf20.ai)
- Lawyers warn of discrimination risks around lack of menstrual health support in the workplace
- OB/GYN-founded vitamin company pledges US$10m to improve women’s health research
- New treatment could ‘disrupt’ growth of breast cancer tumours
- The slippery slope of presumed consent in post-humous reproductive health cases
- Women’s health content censored and blocked on social media
Receive updates from Femtech World
- Femtech World Awards4 weeks ago
Ground-breaking research to be celebrated at Femtech World Awards
- News2 weeks ago
Start-up secures Series A funding round for wearable urinary incontinence device
- News3 weeks ago
Partnership to pilot ‘cutting-edge’ embryo selection tool
- News1 week ago
Irish clinic launches menopause app to help researchers develop new treatments
- News2 weeks ago
Start-up raises US$1.7m to tackle breast cancer in women with dense tissue
- News3 days ago
US fertility clinic network raises US$20m to ‘democratise’ IVF
- News4 weeks ago
McKinsey report underscores US$1tn potential of closing gender health gap
- News2 weeks ago
‘No more cute mentorship programmes’: femtech community reacts to Women’s Health Strategy